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Abstract
Background: One of the main uses of seroprevalence studies it to evaluate vaccination
programmes. In 1998, a programme of universal vaccination of preadolescents in schools with the
hepatitis A vaccine was begun in Catalonia. The objective of this study was to investigate the
prevalence and risk factors of hepatitis A virus infection (HAV) in a sample of the adult population
of Catalonia in 2002 and to evaluate the changes with respect to a survey carried out in 1996.
Methods: The prevalence of HAV antibodies was determined by a third generation competitive
immunometric assay in a representative sample of 1292 people aged >15 years. The association
between the prevalence and different sociodemographic variables was determined by multiple
logistic regression analysis.
Results: The standardized global prevalence of HAV antibodies in 2002 was 68.2%, increased with
age (p < 0.0001) and was associated with being born outside Catalonia (OR: 1.75; 95% CI 1.11–
2.76) and lower social class (OR: 1.14; 95% CI 1.05–1.25). Compared with the last survey carried
out in 1996 the standardized global prevalence was lower (68.2% vs 77.8%; p < 0.0001) as was the
prevalence in people under 45 years.
Conclusion: The prevalence of the hepatitis A virus is decreasing in the adult population of
Catalonia, especially in the younger age groups. The programme of vaccination of adolescents
begun in 1998 to control the disease can provide indirect protection to the unvaccinated
population.
Background
Hepatitis A virus infection (HAV) has decreased substan-
tially in developed countries in recent decades, due to
improvements in the quality of the water supply and the
treatment of human residual wastes [1]. However, in these
countries, the rates of clinical disease may increase, since
the virus circulates less, infections in childhood (which
are usually asymptomatic) are less frequent, and infec-
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symptoms, increase. Although most cases are benign, the
disease may present relapses or a prolonged course and
produce extrahepatic complications, fulminant hepatitis
or even death [2-4].
The availability of a hepatitis A vaccine since the middle
of the 1990s, with a high degree of efficacy [5,6] and effec-
tiveness [7,8] has increased discussion on the vaccination
strategy to a disease with an exclusively human reservoir
and which is therefore potentially eradicable [9].
Although current strategies are centred on the control and
not the eradication of the disease [10], it is important to
determine the pattern of hepatitis A virus infection in each
community in order to optimize vaccination strategies.
In Catalonia, the hepatitis A vaccine was introduced in
1995 and was recommended for persons belonging to risk
groups. At the end of 1998, a pilot programme of vaccina-
tion of preadolescents at 12 years of age in schools with
the combined hepatitis A+B vaccine was begun, and every
school year a coverage > 90% was reached[11].
Seroprevalence studies are recognized to be useful tools to
evaluate the impact of vaccination programmes [12].
The objective of this study was to determine the preva-
lence of hepatitis A antibodies in the adult population of
Catalonia and to compare the results with those obtained
in the surveys carried out in 1989 and 1996 using a similar
methodology [13,14].
Methods
The study was carried out in 2002. The population sample
was obtained in a two-stage process. Firstly, 97 municipal-
ities were selected randomly after stratification into urban
(>10,000 inhabitants) and rural (≤10,000 inhabitants)
habitat. Secondly, individuals to be included in the study
were selected randomly from the municipal census lists.
Written informed consent was sought from all partici-
pants. The study was approved by the Bioethics Commit-
tee of the Department of Health.
The sample size was calculated using an alpha error of 5%
and a precision of ± 0.025, with an expected prevalence of
antibodies of 50% (the least favourable situation), corre-
sponding to a theoretical sample size of 1,600 people.
Sera samples were kept frozen at -40°C until analysis in
the microbiology laboratory of the Hospital Clinic of Bar-
celona.
Total HAV antibodies were determined by a commercial
third-generation competitive immunometric assay (ETI-
AB-HAVK-3; DiaSorin, Saluggia [Vercelli], Italia) accord-
ing to the manufacturer's instructions.
Sociodemographic variables were collected by a question-
naire that included age, sex, social class, municipality of
residence and place of birth. The municipality of resi-
dence was classified as rural (<10,000 inhabitants) or
urban (≥10,000 inhabitants). Social class was determined
using the occupation (or the occupation of the parents in
schoolchildren) according to the English classification
[15]. Age and sex standardized prevalences for 1989, 1996
and 2002 were calculated using the Catalan population of
2001 as the standard population. Thus, the global preva-
lence was obtained by weighting the prevalence from dif-
ferent age group and taking into account the distribution
of the Catalan population in 2001 [16].
The standardized global age and sex prevalence and the
age specific prevalences of HAV antibodies were com-
pared with the prevalences obtained in the 1989 and 1996
studies in representative samples of the Catalan popula-
tion using the same methodology [13,14]. The differences
between proportions were compared using the Chi-square
and Fisher tests. The level of statistical significance was
established at p < 0.05.
The Odds Ratio and the 95% confidence intervals (CI)
were calculated for the sociodemographic variables. A
multiple logistic regression analysis was carried out
including age, sex and the variables that were significant
in the bivariate analysis.
The statistical analysis was performed using the SPSS for
programme Windows version 10 (SPSS Inc, Chicago, Ill,
USA).
Results
The final sample obtained was 1292 persons, a global par-
ticipation of 81%. The distribution of the sample was sim-
ilar to that of the Catalan population. The standardized
global prevalence of hepatitis A antibodies was 68.2%,
lower than the standardized prevalence of 77.8%
obtained in the 1996 study; the difference was statistically
significant (p < 0.0001). The differences observed
between the standardized global prevalence of the 1989
(84.3%) and 1996 (77.8%) studies were also statistically
significant (p = 0.002).
The distribution of the seroprevalences obtained in 1989,
1996 and 2002 according to age group is shown table 1.
In the three studies, the prevalence of antibodies increased
with age (p < 0.0001). In 2002, the 15–24 years, 25–34
years and 35–44 years age groups had prevalences of
15.4%, 34.9% and 75.1%, respectively, all inferior to the
corresponding age groups in the 1996 study (31.4%,Page 2 of 5
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nificant (p = 0.004, p < 0.0001 and p = 0.002, respec-
tively).
In the univariate analysis of the sociodemographic varia-
bles, significant differences were detected for the place of
birth (OR: 4.57; 3.15–6.66) and social class (OR: 1.72;
1.31–2.27) (table 2). These associations were maintained
in the multivariate analysis, with adjusted OR of 1.75
(1.11–2.76) and 1.14 (1.05–1.25), respectively.
Discussion
The standardized prevalence of hepatitis A virus infection
in the adult population of Catalonia decreased globally by
10% during the years 1996–2002, while the reduction
during the period 1989–1996 was only 8%. In the 1996–
2002 period, the decrease was greatest in the youngest age
groups: 51% in the 15–24 years age group, 39% in the 25–
34 years age group and 14% in the 35–44 years age group.
In the 1996 study, at a time when vaccination was only
recommended for risk groups, there was a significant
reduction (31%) with respect to the 1989 study in the 25–
34 years age group but not in the other two groups
[13,14].
It is clear that improvements in hygiene and cleanliness
are determining factors of the prevalence of HAV infection
in the community. However it is not so clear why such
improvements have a higher impact in the adult popula-
tion in the 1996–2002 period than in the 1989–1996
period. In our opinion it is probable that the vaccination
programme of preadolescents begun in 1998 have got
some influence in this reduction.
Both observational studies [7,17] and mathematical mod-
els [12] carried out in the United States in areas where rou-
tine vaccination is recommended, suggest the hepatitis A
vaccine can not only prevent infection in the vaccinated
population but also provide indirect protection to the
unvaccinated population. In Israel, where universal vacci-
nation with two doses of vaccine at 18 and 24 months of
age was introduced in 1999, and where coverage was 90%
for the first dose and 85% for the second, a high degree of
herd immunity has been observed [18].
In Catalonia, the coverage of the routine vaccination pro-
gramme of preadolescents with the hepatitis A+B vaccine
is greater than 90% [19] and when the present study was
carried out four cohorts had already been vaccinated.
Thus it is plausible to suggest that the indirect effect of the
vaccination could explain at least in part, the reduction in
the prevalence of the infection observed in adults between
1996 and 2002.
The fact that the greatest reductions in prevalence
occurred in young people and young adults might be
because these age groups have more contact with the vac-
cinated population and therefore benefit more from the
reduction in the circulation of the virus as a consequence
of vaccination.
The fact that the prevalence has not decreased in older
people suggests a cohort effect. This may be because older
people had a greater probability of becoming infected due
to poorer hygiene and sanitation in the past [20].
The available data on disease incidence also corroborate
the benefits of universal vaccination. Thus, the reported
incidence of the disease in Catalonia in 1996–1998 was
6.2 per 100,000 globally and 10.3 for the 10–14 years age
group, whereas after the introduction of universal vaccina-
tion, the respective figures for 1999–2001 were 2.6 and
1.8 per 100,000 [11]. However, because hepatitis A inci-
dence shows cyclic increases and decreases, determining
how much of the declines observed has resulted from vac-
cination is complicated [21]; besides, in population-
based studies we don't have the benefit of a control com-
munity [7].
Table 1: Prevalence of HAV antibodies according to age groups. Catalonia, 1989, 1996 and 2002.
Age groups 1989 Prevalence 1996 Prevalence 2002 Prevalence
% (95%CI) n % (95%CI) n % (95% CI) n
15–24 43.1 (31.4–55.3) 72 31.42 (23.1–40.5) 118 15.42 (9.8–22.6) 136
25–34 82.11 (72.3–89.6) 84 56.91,3 (50.1–63.6) 216 34.93 (28.7–41.6) 223
35–44 93.8 (88.1–97.3) 129 86.94 (81.8–91.1) 222 75.14 (69.4–80.1) 265
45–54 95.4 (89.5–98.5) 108 95.5 (91.9–97.8) 222 93.8 (90.3–96.4) 276
55–64 91.0 (82.4–96.3) 78 99.1 (96.8–99.9) 224 97.3 (94.3–99.0) 224
>64 96.1 (90.3–98.9) 102 98.8 (96.6–99.8) 257 98.2 (94.9–99.6) 168
TOTAL* 84.34 (81.3–87.3) 573 77.8 4,1 (75.5–80.1) 1259 68.21 (65.7–70.7) 1292
1p < 0.0001 2p = 0.004 3p < 0.0001 4p = 0.002
* Standardized by age and sexPage 3 of 5
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a greater prevalence of HAV antibodies were being born
outside Catalonia and belonging to the lower social
classes. Migration normally involves a flow from less-
developed rural nuclei to urban nuclei and it is probable
that this explains the association found [22,23].
Likewise, the association between the prevalence of anti-
bodies and the lower socioeconomic level also coincides
with the results of other studies [4,24,26].
Taking into account the difficulty of obtaining high vacci-
nation coverages in those population groups with a
greater risk of infection and also the fact that vaccination
coverages are very high in Catalonia, the strategy of uni-
versal vaccination is, in our opinion, the best option. The
greatest drawback of routine vaccination is the cost of the
vaccine [10]. The hepatitis A+B vaccination programme
implemented in Catalonia, with the substitution of the
hepatitis B vaccine by the A+B vaccine, has been shown to
be highly efficient [27].
Conclusion
The results of this study, carried out four years after the
introduction of a pilot programme of vaccination of prea-
dolescents with the hepatitis A+B vaccine in Catalonia in
1998, indicates that the prevalence of HVA has decreased
in the adult population, especially in the younger age
groups and suggest that vaccination should continue, as
probably it has contributed to reducing the circulation of
the virus in young adults and to a smaller risk of becoming
infected.
Continuation of routine vaccination is also supported by
the fact that the reduction in the prevalence of HAV infec-
tion in the adult population in Catalonia, especially in the
younger age groups, will favour both a shift in clinical
cases of the infection to older age groups and the appear-
ance of outbreaks [10,28-30]. This phenomenon has been
observed in other southern European countries [30,31] as
also in Catalonia [33].
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